â ī¸ Always consult cardiology before discontinuing antiplatelet therapy after stent insertion.
đĢ Stopping clopidogrel or other antiplatelets too early (especially with drug-eluting stents) risks catastrophic in-stent thrombosis.
đ Standard practice: Dual Antiplatelet Therapy (DAPT) â aspirin + clopidogrel/ticagrelor/prasugrel â for 6â12 months, with aspirin often lifelong.
đ Local / guideline variations exist, so confirm with the cardiology team.
âšī¸ About
- PCI (Percutaneous Coronary Intervention): Opens blocked coronary arteries using balloons and stents to restore perfusion. Improves angina symptoms and quality of life, though elective PCI does not significantly reduce overall mortality.
- Originally developed to select candidates for CABG, PCI is now a primary treatment for many acute coronary syndromes (ACS).
- Widespread catheterization labs, even in district hospitals, allow rapid reperfusion without immediate need for cardiac surgery backup.
đ§Š Stents
- đ ī¸ Stents = metallic scaffolds to keep an artery open after balloon angioplasty.
- đ Deployed via femoral or radial approach using guidewires and balloons under fluoroscopy.
- đ Drug-Eluting Stents (DES): Coated with antiproliferative drugs (e.g., sirolimus, paclitaxel) to reduce restenosis risk. Preferred in diabetics and complex lesions.
- ⥠Difficult lesions: Long, calcified, eccentric, bifurcation, thrombotic, or tortuous arteries.
- 𩸠DAPT: Almost all patients receive aspirin + clopidogrel (or ticagrelor/prasugrel) for 6â12 months after PCI.
đĨ Indications (Mortality Benefit)
- đ¨ STEMI: Primary PCI within 90 minutes of first medical contact.
- đ STEMI with hemodynamic compromise or failed thrombolysis.
- ⥠STEMI in thrombolysis-contraindicated patients (e.g., recent intracranial hemorrhage).
đ Other Indications
- High-risk NSTEMI.
- Unstable angina with high-risk features.
- Unexplained ischemic cardiomyopathy.
- Survivors of cardiac arrest where ischemia is suspected.
- Significant ventricular arrhythmias (VT) due to ischemic substrate.
đ Vascular Access
- Common sites: Radial artery (preferred for lower bleeding risk), femoral artery, or brachial artery.
đ Protocol
- đī¸ Consent: Mortality risk ~0.1% for diagnostic angiography, higher with PCI complexity.
- 𩸠Pre-procedure checks: FBC, platelets, U&Es, renal function, glucose, and peripheral pulses.
- đ Consider acetylcysteine in renal impairment (contrast nephropathy prevention â though evidence is mixed).
- đĢ Fast for 6 hours, continue aspirin, load clopidogrel/ticagrelor as advised.
âī¸ Interventions
- đ Balloon Angioplasty: Rarely used alone; risk of restenosis high.
- đ§ą Bare Metal Stents (BMS): Reduce restenosis vs balloon, but higher thrombosis risk. Shorter DAPT course than DES.
- đ Drug-Eluting Stents (DES): Reduce neointimal hyperplasia and restenosis; require longer DAPT.
- đ Referral for CABG: Triple-vessel disease or significant left main stem involvement.
â ī¸ Post-Procedure Complications
- đ Bleeding: At access site or retroperitoneal (suspect if hypotension + tachycardia).
- đĻĩ Limb Ischemia: Cold, pale leg from thrombosis or dissection â urgent vascular review.
- đ Acute Stent Thrombosis: Presents like STEMI â urgent repeat PCI.
- đ§ Contrast Nephropathy: Monitor U&Es, hydrate well.
- đ§ Stroke: Rare but serious embolic complication.
- đĻ Infection / pseudoaneurysm / AV fistula: At puncture site, confirmed by ultrasound.
đ Exam Tip:
đ Always mention DAPT duration when discussing PCI.
đ Drug-eluting stents reduce restenosis but require longer antiplatelet therapy.
đ Radial access = fewer bleeding complications vs femoral.